Tag: Nominations
-
Company of the Year: Therapeutics Development
Cellestial Health is proud to be named the UK Company of the Year 2026 in the field of Therapeutics Development by Excellence Awards. Entries are judged against a number of criteria including:✦ Innovation✦ Strategic thinking✦ Measurable impact✦ Operational excellence “True business excellence emerges when innovation is combined with clarity, adaptability, and responsible leadership,” says Dr…
-
#Killer50: Celebrating Cambridge Cluster
It is our great pleasure at Cellestial Health to be recognised alongside our outstanding peers in the Cambridge ecosystem at the annual #Killer50 2026 event by Business Weekly.We will strive to continue delivering advancements in the treatment of brain disorders for the benefit of patients and the scientific community. With gratitude, always 🙏 About #Killer50:Organised…
-
One Nucleus Awards Gala
Last Thursday 19th of March brought the UK-wide life sciences ecosystem leaders together for a very special occasion of the #ONAwards26 celebration at No.11 Cavendish Square in London. It was a great honour to have the project between Cellestial and The University of Manchester, supported by a Parkinson’s UK grant, recognised as one of the finalist entries in the “Best Industry and…
-
Best Industry and Not for Profit Collaboration: Finalists
The annual One Nucleus Awards dinner celebrates the excellence of the diverse Life Sciences sector, recognising all parts of the community. One Nucleus believe that it is the interactions and dynamics of the entire ecosystem that lead to successful value and impact creation, the vision that resonates with our team’s. This year, the collaboration between…
-
Dazzling Dinner with Cambridge Independent
On Thursday 25th of September Cambridge Independent hosted a Gala dinner to celebrate the 2025 edition of the #CIBusinessAwards at King’s College, Cambridge. The event celebrated a range of local businesses from all sectors, from property management to educational opportunities. It is not easy to stand out in such a diverse environment, and in a…
-
New Chapter for the Kingdom of Saudi Arabia
On October 1-2, King Abdullah International Medical Research Center (KAIMRC) in partnership with J.P. Morgan Asset Management and the Ministry of Investment (MISA) welcomed 10 global finalists startup companies as well as experts from the biotech and pharmaceutical industry in Riyadh at the #LSIF2025, hosted at #KSAUHS Convention Centre.This event supports the goal of SaudiArabia…
-
Finalists: OBN Awards 2025
Cellestial Health has been honoured as one of the top four companies in the BioSeed “Ones to Watch” category: https://obn.glueup.com/event/obn-awards-2025-128684/2025-finalists-announced.html#2025-finalists-announced The Awards, now in the 17th year, celebrate innovation and outstanding achievement across the Life Sciences industry. Being the company “to watch” is thrilling and prestigious, but also comes with a weight of expectation and…
-
Finalists: Cambridge Independent Business Awards 2025
For the second year now, Cambridge Independent newspaper hosts a prestigious Business Awards ceremony, celebrating businesses of all sectors and sizes from the Cambridgeshire region in a number of categories. Paul Brackley, Editor and Chair of the judging panel, comments in the latest article: “We were impressed by the quality of entries and it was…
-
Cambridge Tech Week: Innovation Alley Shortlist
This week Cellestial Health has been named one of 47 finalists in the Innovation Alley pitching competition, part of the Cambridge Tech Week. A variety of sectors was represented including deeptech, climatetech, agritech, batterytech, and so much more, from Cambridge and all around the world. Companies of all sizes and from all (tech-related) sectors were…
-
Strategic Win: Preclinical Development Consultation with L2D
Cellestial Health is one of the preclinical-stage companies that was recently selected for a free consultation with the top experts at Leads to Development (L2D) regulatory consultancy, Jonathan Kearsey and Vincent Dubois. This will provide confidential guidance and advice on the path to the regulatory approval of the first Cellestial drug asset. As Nat Hastings,…